Drugs / Pembrolizumab coformulated with berahyaluronidase alfa
Pembrolizumab coformulated with berahyaluronidase alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07513376 | May 2026 → Aug 2034 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab coformulated with berahyaluronidase alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513376 ↗ |
| Route | Subcutaneous | “Participants will receive intismeran 1 mg via intramuscular (IM) injection plus pembrolizumab coformulated with berahyaluronidase alfa 790 mg via subcutaneous (SC) injection” NCT07513376 ↗ |